Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the recent results of two pre-clinical Probudur™ dose escalation studies.
Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies Read More